Genetic polymorphisms in CYP2C8 can influence the metabolism of important therapeutic
agents and cause interindividual variation in drug response and toxicity. The significance of …

Research investigating CYP2C8 as a drug-metabolizing enzyme has gained momentum
over the past few years. CYP2C8 is estimated to oxidatively metabolize approximately 5% of …

Abstract Cytochrome P450 CYP2C9 metabolizes a wide variety of clinically important drugs,
including phenytoin, tolbutamide, warfarin and a large number of non-steroidal anti …

Human CYP2C8 is a key member of the CYP2C family and metabolizes more than 60
clinical drugs. A number of active site residues in CYP2C8 have been identified based on …

Cytochrome P-450 (CYP) 2C9 CYP2C9 is a polymorphically expressed enzyme responsible
for the metabolism of several clinically important drugs, some with a low therapeutic index …

CYP2C9 is a polymorphic enzyme that metabolizes a number of clinically important drugs. In
this study, catalytic activities of seven alleles found in Japanese individuals, CYP2C9* 3 …

CYP2C9 metabolizes more than 100 clinically used drugs including phenytoin, S-warfarin,
tolbutamide, glipizide, diclofenac, and losartan with varying contributions. CYP2C9 is …

CYP 2C8, which carries out the oxidative metabolism of at least 5% of clinical drugs, has
attracted increasing attention in recent years. New drugs (substances), inducers and …

Human cytochrome P450 2C9 (CYP2C9) accounts for∼ 20% of hepatic total CYP content
and metabolizes∼ 15% clinical drugs such as phenytoin, S-warfarin, tolbutamide, losartan …

Abstract CYP2C9 metabolizes approximately 20% of clinically used drugs, including the
narrow therapeutic window drugs warfarin and phenytoin. More than 16,000 variants have …